Herein, we report the modular synthesis and evaluation of a prostate-specific membrane
antigen (PSMA) targeted small molecule drug conjugate (SMDC) carrying the …

New targeted chemotherapeutics are urgently needed to minimize off-target toxicity and
reduce the high-mortality rate associated with metastatic prostate cancer. Herein, we report …

We developed a model small-molecule drug conjugate (SMDC) that employed doxorubicin
as a representative chemotherapeutic targeted to the cell membrane biomarker PSMA …

This work describes the enhancement of a novel antitumor therapeutic platform that
combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug …

Targeting therapy is a concept that has gained significant importance in recent years,
especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate …

Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is
conjugated to a targeting vector, for specific delivery to the tumor site. This promising …

Small molecule drug conjugates are an emerging targeted therapy for cancer treatment.
Building upon the overexpressed prostate-specific membrane antigen (PSMA) in prostate …

The tunable nature of phosphoramidate linkers enables broad applicability as pH-triggered
controlled-release platforms, particularly in the context of antibody-and small-molecule-drug …

Prostate-specific membrane antigen (PSMA), a type II membrane glycoprotein, its high
expression is associated with prostate cancer progression, and has been becoming an …

A strategy for stereoselective synthesis of molecular platform for targeted delivery of bimodal
therapeutic or theranostic agents to the prostate-specific membrane antigen (PSMA) …